Indivior Data Reinforces Injectable Buprenorphine's Overdose Risk Reduction
Event summary
- Indivior presented data at the ASAM 2026 Annual Conference demonstrating that monthly extended-release buprenorphine (SUBLOCADE) accounted for the smallest proportion of non-fatal and fatal overdose events among MOUD treatments.
- A retrospective study of over 45,000 patients in Ontario, Canada, found that patients with higher MOUD coverage (over 80%) experienced fewer overdoses.
- The ROUTE study indicated that individuals in remission from opioid use disorder (OUD) exhibited lower craving, withdrawal, and improved quality of life compared to those not in remission.
- Indivior’s long-acting injectable therapy has been prescribed to over 500,000 people.
The big picture
The data reinforces the growing recognition of remission as a key treatment outcome in OUD, moving beyond simple abstinence. This shift in focus, coupled with the demonstrated overdose risk reduction associated with monthly injectable buprenorphine, positions Indivior favorably within a market increasingly focused on comprehensive and sustained treatment approaches. However, the company's reliance on a single, controlled-substance product creates inherent risks related to regulatory oversight and potential for diversion.
What we're watching
- Market Adoption
- The continued uptake of injectable buprenorphine will depend on reimbursement policies and physician willingness to transition patients from oral formulations, potentially influenced by the data presented.
- Regulatory Scrutiny
- Given the REMS program and potential for abuse, Indivior will likely face ongoing scrutiny from regulatory bodies regarding the safe distribution and use of SUBLOCADE.
- Competitive Landscape
- The emergence of alternative MOUD therapies and the potential for generic competition will pressure Indivior to demonstrate the long-term clinical and economic value of its injectable product.
Related topics